MarketInOut Stock Screener Log In | Sign Up

Atara Biotherapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Atara Biotherapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization80.4 mln
Float6.93 mln
Earnings Date10/29/2026

Piotroski F-Score

2 / 9
Weak

Beneish M-Score

-2.93
Likely reliable

Relative Strength

12 / 100
Significantly lagging

Pre-Tax Margin

-269%
Severely loss-making

ROE

44.67
Very strong

Altman Z-Score

-136
Deeply distressed

Business Description

Founded in 2012 and based in Thousand Oaks, California, Atara Biotherapeutics is a clinical-stage company working to create new treatment options for patients with cancer and immune system disorders. Its most advanced program, tabelecleucel, uses the body's own immune cells to fight diseases caused by the Epstein-Barr virus, including a serious condition that can develop after organ or stem cell transplants. The company is also advancing a next-generation cell therapy aimed at certain blood cancers and autoimmune conditions, and conducts its research in partnership with two leading medical institutions.

Key Fundamentals

EPS-1.30
ROE44.67
RPS0.44
ROIC-82.20
ROA-64.19
Interest Cover-5.04
EBITDA, mln-13.71
EV / EBITDA-13.58
EV / EBIT-13.45
Revenue, mln6.19
EV / Revenue30.05

Quote Details

Last 8.01
Change -0.52 (-6.1%)
Open 8.53
Volume 29,930
Turnover 239,739
Average Volume 28,760

Financial Ratios

Pre-Tax Profit Margin-269
Current Ratio1.98
Price / Sales14.51

Financial Strength

Altman Z-Score-136
Piotroski F-Score 2 / 9
Beneish M-Score-2.93
Short Ratio8.52
Short % of Float4.76

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -6.75% 14 / 100   
1 Month -5.32% 39 / 100   
2 Months 3.89% 81 / 100   
6 Months 63.47% 97 / 100   
1 Year -43.03% 21 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog